Latest Industry Updates
Stay up to date with the latest industry updates from the global drug development technology industryLatest Update
Novo Nordisk has announced positive results from phase 3 trial with long-acting factor IX, glycopegylated recombinant factor IX (N9-GP), for treatment of haemophilia...
> read more
News
NW Bio commences Phase III trial of DCVax-L for brain cancer
Northwest Biotherapeutics (NW Bio) has announced the commencement of a Phase III trial with DCVax-L for brain cancer at King's College Hospital in the...
FDA approves Xofigo prostate cancer drug
The USFDA has approved Xofigo (radium Ra 223 dichloride) for the treatment of advanced prostate cancer three months ahead of schedule under the priority review...
Trillium completes dosing in Phase I cystitis/bladder pain syndrome study of TTI-1612
Trillium Therapeutics, a wholly-owned subsidiary of Stem Cell Therapeutics has completed dosing in patients with interstitial cystitis/bladder pain syndrome (IC/BPS) in the Phase I study of...
Sanofi, Regeneron announce patient enrolment in sarilumab Phase III trials
Sanofi and Regeneron Pharmaceuticals have announced patient enrolment in two Phase III trials, Compare and Ascertain, to assess sarilumab as a treatment for rheumatoid arthritis...
Soligenix commences Phase I paediatric Crohn's disease study of SGX203
Clinical-stage biopharmaceutical company Soligenix has initiated a Phase I study of SGX203 (oral beclomethasone 17,21-dipropionate or oral BDP) to treat paediatric Crohn's...
Mirna initiates Phase I trial of anti-cancer drug MRX34
MicroRNA therapy developer Mirna Therapeutics has commenced a Phase I trial of anti-cancer drug...
OncoMed initiates Phase Ib/II small cell lung cancer trial of OMP-59R5
OncoMed Pharmaceuticals has initiated a Phase Ib/II trial of anti-cancer stem cell therapeutic OMP-59R5 (Anti-Notch2/3) in small cell lung cancer...
MorphoSys commences patient dosing in Phase II study of lymphoma drug
MorphoSys has commenced patient dosing in a Phase II study of anti-CD19 antibody MOR208 for the treatment of non-Hodgkin's lymphoma...
Relypsa completes enrolment in patiromer Phase III programme to treat hyperkalemia
Clinical-stage biopharmaceutical company Relypsa has finished enrolling patients with chronic kidney disease (CKD) in a pivotal Phase III programme of patiromer for the treatment of...
Eli Lilly reports poor results from Phase III diffuse large B-cell lymphoma study
Eli Lilly and Company has announced that a Phase III study designed to evaluate enzastaurin as a monotherapy in the prevention of relapse in patients with diffuse large B-cell lymphoma (DLBCL)...
Press Releases
Proven Autoclave Design a Long Runner
Top-loading laboratory autoclaves are the longest serving stalwarts of the Priorclave steam steriliser range, a 100l model being the first produced and to leave the company's factory in 1988...
Bachem Adds 11 New Research Products to Online Catalogue
Bachem is continuously expanding and updating its extensive range of biologically active peptides, amino acid derivatives, biochemicals and immunology...
Meet Biovian at BioTrinity 2013 - European Biopartnering and Investment Conference - 14-16 May 2013, Newbury, UK
Meet Biovian at BioTrinity 2013 - European Biopartnering and Investment Conference - 14-16 May 2013, Newbury,...
New Mammalian cGMP Cell Banking Facility Commissioned by Fujifilm Diosynth Biotechnologies
Fujifilm Diosynth Biotechnologies has announced that it has commissioned on time its new mammalian cGMP Cell Banking Facility (CBF) at its Billingham, UK site....
Tissue Solutions to Exhibit at 2013 BIO International Convention, Booth 4438, Apr 22 - 25, 2013, in Chicago IL, US
Tissue Solution invites pharmaceutical and biotech companies to visit booth 4438 at this year's BIO International Convention 2013. We will be showcasing our unique tissue acquisition service...
Autoclave Manufacturer Priorclave Celebrates 25 Years in Business
British autoclave manufacturer Priorclave celebrated 25 years since first opening its doors for business on the 16th February 1988 and during this period has delivered from its London...
Bachem Signs Peptide-Protein Conjugate Contract with Axon Neurosciences
Bachem and Axon Neuroscience SE today announced that the two companies have entered into a collaboration under which Bachem manufactures Axon's investigational API and supplies it as a...
Bachem Adds 13 New Immunology and Peptide Products to Online Catalogue
Bachem is continuously expanding and updating its extensive range of biologically active peptides, amino acid derivatives, biochemicals and immunology products....
13 New Products Available from Bachem
Bachem is continuously expanding and updating its extensive range of products for your research purposes....
Kemwell Signs Contract Manufacturing Agreement with Mercury Pharma Group
Kemwell today signs an agreement with Mercury Pharma Group for contract manufacture of pharmaceuticals in the new state-of-the-art production facility in Uppsala....
Twitter
Facebook